The aim of this study is to explore the actual situation of prostate cancer in a cohort of healthy population in Saudi Arabia and to show the feasibility of screening for this disease using the internationally agreed criteria. This study was conducted in the city of Riyadh, in the outpatient clinics of four different health facilities. All men presented to the outpatient clinics during the period of study, from January 2008 to December 2008, were invited to participate in the study, in which they were subjected to PSA blood testing and digital rectal examination (DRE). When either test was abnormal, transrectal ultrasound and multiple prostatic biopsies were performed for confirmation of the results. A total of 2100 healthy males who met the inclusion criteria of the study were evaluated. The highest percentage of men with PSAX4 ng ml -1 was in the age group 61-70, 51-60 years (42.7 and 31.8%, respectively). The number of subjects with an elevated PSA only was 172 (8.1%). Those having both elevated PSA and an abnormal DRE were 51 (2.4%). The total number referred to biopsy was 223. Fifty two subjects had a positive diagnosis of prostatic adenocarcinoma, which compromised 2.5% of the cohort studied. The cancer in 27 (52%) persons was organ confined, whereas in 14 (26.9%), it was metastatic. The prevalence rate of prostate cancer detected by screening was higher than expected and the disease was advanced. Larger community-based larger studies are highly warranted specially among high-risk groups.
Introduction
Screening for prostate cancer aims to decrease mortality and morbidity from the disease by increasing the chances of successful treatment through early detection. Currently, there is a lack of evidence to establish whether screening achieves this aim. This is illustrated by the conflicting recommendations offered by medical organizations. The National Cancer Institute, the United States Preventive Services Task Force, and the American College of Preventive Medicine do not endorse screening for prostate cancer in the general population or high-risk groups. 1, 2 In contrast, the American Cancer Society and the American Urological Association recommend annual screening for all men aged 50 years and older, who have a life expectancy of at least 10 years and commencing at an earlier age (40-45 years) for men in high-risk groups such as African Americans and those with affected first-degree relatives. 3, 4 In the absence of evidence, patients must rely on their own beliefs and guidance from doctors to make an informed decision. However, if a patient must live with the consequences of a medical decision, then the opportunity to accept or reject the decision must be made available to the patient. This has encouraged patients and doctors to adopt a shared approach to healthcare. 5 The incidence of prostate cancer in the Saudi Arabia is very low in comparison with Persian Gulf and other European countries. Although the latest agestandardized incidence rates of prostate cancer, 2004, in the Kingdom were 5.1/100 000, the reported figures for Kuwait, Bahrain, and Qatar were 16, 11.8, and 10.2, respectively. 6, 7 In United States, the age-standardized incidence rate is much higher, that is 145.3. The figures reported from the national cancer registry of Saudi Arabia depended mainly on hospital-based approaches and no community-based studies were conducted for exploring the actual situation of prostate cancer in the Saudi Arabia disclosing these low figures. This study was undertaken as a trial to explore the actual situation of prostate cancer in a cohort of healthy population in Saudi Arabia and to show the feasibility of screening for this disease using the internationally agreed criteria.
Materials and methods
This study was conducted in the city of Riyadh, the capital of Saudi Arabia, which occupies the second rank for the incidence of prostate cancer after the Eastern region of the country, in the outpatient clinics of four different health facilities, that is main university hospital (King Khalid University Hospital) and three primary health care centers selected randomly and representing three different regions in the city. The fieldwork was conducted after getting the approval from the ethics committee of the faculty of medicine, King Saud University. Standing posters were positioned at each place of the study settings, inviting men to participate and describing the nature, objectives, and benefits of the study. In addition, advertisements were displayed in the local newspaper to encourage men to participate in the study. The study period was 1 year, from January 2008 to December 2008. Inclusion criteria were all men above 50 years of age (or above 40 years, if at risk), such as black ethnicity or a positive family history. Patients accepting to participate signed an informed consent to be included in the study. Those with a history of coagulopathies or sepsis were excluded .The total sample at the end of the year amounted to 2100 men. All participants were subjected to blood testing for PSA determination and digital rectal examination (DRE) by trained professionals. When either test was abnormal, transrectal ultrasound and multiple prostatic biopsies were performed. The ultrasound test includes a thorough examination of the prostate glands including notation of its dimension for size calculations as well as evaluation of hypoechoic areas suspicious for cancer. The biopsy needles were guided by the transrectal ultrasound into the prostate gland. They were performed after adequate antibiotic coverage and 10 ml of lidocaine local anesthetic injected into the periprostatic bundle. An 18-gauge needle was used to obtain eight-core systemic biopsies. A classic sextant biopsy of the peripheral zone plus two of the transition zone. They were submitted then in separate bottles to a pathologist. An abnormal PSA is defined as any level X4 ng ml -1 , and if the patient is on 5 Alpha reductase inhibitors at any level above 2 ng ml -1 . An abnormal DRE is defined as any nodularity, asymmetry, or irregularity in shape or firmness of the prostate gland. Any patient diagnosed with prostate cancer was offered treatment depending on his cancers stage and grade as well as his general health condition. The patient was made aware of all the treatment options, including watchful waiting, radical prostatectomy, and radiation therapy. Those with a negative biopsy were offered continual annual screening.
Collected data was analyzed and tabulated in the form of frequencies and percentages. Age of the participants was categorized into four categories: 40-50, 51-60, 61-70, and 470 years. Then the PSA values were analyzed accordingly; as we do not have PSA population norms, we could not show the percent of participants in reference to age-related PSA population norms.
Treatment policies
The treatment of prostate cancer was performed according to the international policies and guidelines.
Results
A total of 2100 healthy male subjects who met the inclusion criteria of the study and agreed to participate in the study were evaluated. Most of the study participants were married (96%), those with education of secondary school and high school were 32 and 46%, respectively. Only 5% of our sample were earlier subjected to PSA testing. The age distribution, the average PSA values, and those with elevated PSA (X4 ng ml -1 ) is shown in Table 1 , in which the mean PSA values were elevated in the older age group; The highest percentage of men with elevated PSA were in the age group 61-70, 51-60 years (42.7 and 31.8%, respectively) ( Table 2 ).
The number of subjects with an elevated PSA was 223 (10.6%) and the number of subjects with an abnormal DRE was 105 (5%). Those having both elevated PSA and an abnormal DRE were 51 (2.4%). The total number of subjects referred to transrectal ultrasound and biopsy because of an abnormal finding was 223, of whom 91 refused the biopsy because of fear and/or stigma associated with cancer confirmation and deficient health background or could not be reached. One hundred and thirty two subjects underwent transrectal ultrasound and biopsy. This is shown in Table 3 . Fifty two subjects had a positive diagnosis of adenocarcinoma of the prostate. This compromised 2.5% of the cohort studied, the percent of subjects having a positive biopsy out of those referred for a biopsy was 39.3%. Mean Gleason score distribution and stage at diagnosis are shown in Tables 4  and 5 , in which it seems that 417% of the confirmed cancer cases had a high grade for Gleason score (nearly 27% of them were metastatic and 21% were locally advanced cases).
Discussion
This is the first field trial study conducted in the Saudi Arabia attempting to clarify the true figure of prostate cancer and to study the importance and feasibility of prostate cancer screening. When considering populationscreening programs, the benefits and harms must be carefully assessed, and the benefits should always outweigh the harms. Although evidence does not yet support population screening for prostate cancer, there is considerable demand for the PSA test among men worried about the disease, specially among relatives of prostate cancer patients. 5 Despite the lack of evidence of the effectiveness of screening in reducing mortality from prostate cancer, increased testing for PSA has certainly contributed to the rising incidence of prostate cancer in some countries such as United Kingdom. 8, 9 The debate over prostate cancer screening still rages on, despite the release of results from two large randomized clinical trials. The first one revealed that PSA-based screening reduced the rate of death from prostate cancer by 20%, but was associated with a high risk of over diagnosis. 10 The second study indicated that the rate of death from prostate cancer was very low and did not differ significantly between the screened and non screened population. 11 Although systematic parasagital sextant biopsy has been the standard protocol for many years, studies applying extended protocols have shown that the sextant biopsy misses 10-30% of the cancers. A significant number of men need to undergo repeat biopsy because Prostate cancer screening DM Rabah and MA Arafa of clinical indications. The ideal biopsy protocol remains to be determined. More extensive biopsy protocols obtaining a minimum of eight tissue cores, particularly from the lateral peripheral zones, should be performed. 12 We chose to add two transition zone biopsies because although the majority of tumors arise in the peripheral zone, up to 24% of prostate cancers originate in the transition zone. 13 It still needs to be clarified whether the future lies in performing biopsies more laterally, increasing the number of biopsies to 10, 12, 15, or even 18 or simply repeating the sextant biopsy scheme. 14 Despite the low figures of prostate cancer in Saudi Arabia in comparison with other Persian Gulf countries and European ones, this study revealed 2.5% prevalence of prostate cancer among our studied cohort and those who had a positive biopsy out of those who were referred constituted 39.3%. Of the confirmed cancer cases, 417% had a high grade for Gleason score and nearly 27% were metastatic. This is the first screening study for prostate cancer conducted in the Kingdom. During the early phases of a screening program, the pool of patients with advanced but asymptomatic disease who were not diagnosed is higher. As screening becomes more established and wide spread, the numbers are expected to decline and more localized disease to be the norm; this could account for high prevalence and advanced stage of the discovered cancer cases. In addition, these figures could drive our attention to the under-reporting status of prostate cancer in the Kingdom and in turn delayed diagnosis along with poor awareness among the population and primary health care providers with regards to cancer screening and that we are in need for more elaborative studies to illustrate the actual existing picture of prostate cancer. Although we are not recommending mass screening for population, we feel that the urologist must offer the patients informed opportunistic screening, and the opportunity to accept or reject the decision. More trials and investigations are warranted specially among high-risk population, that is first-degree relatives of cancer patients. One of the important factors, which affects the screening process is the man's knowledge about prostate cancer screening as well as his likelihood of being screened. Increasing knowledge will increase the proportion of men who know the disadvantages and advantages of screening and increase the proportion of men who make informed decisions about prostate cancer screening and decrease stigma and fear-associated cancer.
Limitations of the study
First, the sample size is not large enough to achieve significance; however, this work is considered as a trial study to give us a baseline data for future studies. Second, we cannot determine the efficacy of our screening system, as the follow-up period is not sufficient. The ongoing projects in Riyadh city (screening of cancer among the first-degree relatives and raising their awareness toward cancer screening) may overcome these problems.
Conclusion
The prevalence rate of prostate cancer among our studied cohort detected by screening was relatively higher than expected and more than one fourth had advanced disease and are beyond cure. This study is considered as the basic approach to build on for other community-based larger studies, among high-risk population.
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Study Highlights
This is the first trial fieldwork conducted in The Kingdom of Saudi Arabia, trying to explore the situation of prostate cancer in the Kingdom, the incidence of cancer in this region is very low in comparison with all gulf areas and European countries, the explanation for this phenomenon is unknown, the reported figures from the national cancer registry in the Kingdom is depending only on hospitalbased reports, This study has shown that there is an under-reporting for this cancer and also there is a delay for case detection and diagnosis. We conducted our study in the Riyadh city, the capital, where it has the second highest incidence of cancer in the Kingdom. We began a nationwide fieldwork to screen for prostate cancer among first-degree relative of prostate cancer patients in Riyadh and to follow them up for 4 years. In addition, we will start a genetic and nutritional study, hoping to clarify the actual situation of prostate cancer in this region. The whole project is funded by two important funding agencies in the Kingdom as indicated in the text. The material is original research, has not been earlier published, and has not been submitted for publication elsewhere while under consideration.
